Maria Gemelli

[Maria Gemelli @MariaGemelli89]

Flying back from the EORTC Spring Meeting 2026 in Gdańsk ✈️

Grateful for these inspiring days, great discussions and new connections in oncology research.

#EORTC #Lungcancer

[Jordi Remon @JordiRemon]

Great discussions at the EORTC Lung Cancer Group meeting in Gdańsk. A real privilege to work with such a collaborative and forward-thinking community—especially encouraging to see new voices actively contributing to study design and research priorities. You are welcome!! #EORTC

[Maria Gemelli @MariaGemelli89]

🫁 Can we safely stop #Immunotherapy after 2 years in advanced #NSCLC?

I-STOP tackles one of the most debated questions in #ThoracicOncology.

Discontinuation feasible in selected patients

https://t.co/DfiyTW75sg

#LungCancer #Oncology #OncTwitter #MedTwitter #ICI #immuno

[Jordi Remon @JordiRemon]

Do we need to change the SoC Ttx for Pancoast NSCLC🫁? Cohort of cases treated: induction
CTIO —>Surgery. pCR 100%, strong prognostic marker in these rare 🫁.We discuss challenges to apply this approach in daily practice. High expertise surgery needed

https://t.co/OKWIuBUHgl

[Maria Gemelli @MariaGemelli89]

CIOT 2025 just concluded in Venice: top-notch content and inspiring discussions. Thank you all — see you next year in Palermo! #Oncology #LungCancer #CIOT

[Stephen V Liu, MD @StephenVLiu]

Dr. @TonyMok9 discusses #EGFR at #CIOT25. Emerging combinations like MARIPOSA and FLAURA2 improving outcomes - key is patient selection. Chemo-IO is out based on CM722 and KN789 but HARMONi could change things if OS superior. ADCs in 3L instead of 2L?

[Maria Gemelli @MariaGemelli89]

📢 Now Online!

Happy to share our latest meta-analysis on the role of ICIs in PD-L1 negative NSCLC.

Grateful to all the co-authors

🔗 Full article here: https://t.co/448NWs3jmv

#NSCLC #immunotherapy #lungcancer

[Maria Gemelli @MariaGemelli89]

Exciting days at the EORTC Lung Cancer Group Spring Meeting!
Innovative proposals, great teamwork, and strong support for young researchers.
Happy to be part of this!
#EORTC #LungCancer

[Jordi Remon @JordiRemon]

Cooperative Academic groups like #EORTC Lung Cancer Group are amazing!We have made our Spring meeting in Genova 🇮🇹with an outstanding group of Young Investigators 👏🏻.Lots ideas for future academic trials to ⬆️outcome of pts with 🫁 cancers. Working Together makes us stronger💪🏻

[Maria Gemelli @MariaGemelli89]

Wrapping up my ESMO experience and heading home. It’s been a whirlwind of emotions…..the first time for me as a speaker, exciting new data, and the pleasure of reconnecting with colleagues old and new. Thank you for the incredible moments! #ESMO2024

[Maria Gemelli @MariaGemelli89]

Just returned from WCLC and wanted to extend a huge thank you to the @IASLC Academy for the incredible experience and opportunity! #WCLC2024 #IASLC

[IASLC @IASLC]

A friendly competition among the 2024 IASLC Academy class will culminate at #WCLC24. Participants Sally Lau, MD, and @MariaGemelli89 share thoughts about the experience in #ILCN: https://t.co/SAxzAh3sTa #LCSM

[Benjamin Besse @BenjaminBesseMD]

Stop pembro after 2 years?

In 43,359 pts that received up-front pembrolizumab for an advanced NSCLC, continuation beyond 2 years was not associated with better OS than a fixed 2-year treatment, HR = 0.97 [0.75–1.26] p = 0.95.
@arousseaumd

https://t.co/It7wr78ilx

[Stephen V Liu, MD @StephenVLiu]

Multidisciplinary consensus statement & practical recommendations on neoadjuvant & adjuvant therapy for early stage resectable NSCLC from @IASLC now @JTOonline led by Drs. @DoctorJSpicer and Tina Cascone.
https://t.co/uGzdUy2YYx

[Elio Gregory Pizzutilo @eliogreg]

#ARTICUNO study finally published! @ESMO_Open
📊 largest dataset of #NSCLC with uncommon #EGFR alterations treated with #osimertinib
🧬data on very rare alterations (snv, fusion, KDD), #intracranial activity, and #resistance mechanisms
🔎 #E709 mut->lack of benefit

[Eric K. Singhi, MD @lungoncdoc]

Engaging discussions this morning on our @IASLC Academy projects!

Great to have Academy co-chair @ChristianRolfo join us as our group mentor, providing tailored advice on our initiatives. #lcsm

[Filippo Gallina @filippog92]

@DoctorJSpicer @MThoracics Thrilled and proud to be working with you @DoctorJSpicer, @LyndonCWalsh @MThoracics! Excitedly awaiting the results of other super interesting projects on prognostic and predictive factors in resectable NSCLC!!

[Benjamin Besse @BenjaminBesseMD]

Should we infuse IO in the morning? Intriguing work just published: Circadian tumor infiltration and function of CD8+ T cells dictate immunotherapy efficacy.
We may need to analyze timing of IO infusion in phase III trials to guide us in our daily clinic.
https://t.co/oc1QtoHc7g

[Jarushka Naidoo @DrJNaidoo]

Ph III CM77T trial @NEJM: Periop Nivo in Stage IIA-IIIB NSCLC:

- neoadj nivo+chemo x 4 + 1yr adj nivo v neoadj chemo x 4 + 1yr adj pbo
- EFS HR 0.58 (p<0.001), pCR 25.3% v 4.7% favoring nivo+chemo
- g3+ TRAEs in 32.5% v 25.2%

#TCascone @Oncoalert #LCSM
https://t.co/Gmn1TV5BRS

[Stephen V Liu, MD @StephenVLiu]

US FDA accepts for priority review BLA of zenocutuzumab (HER2/3 bispecific antibody) for patients with #NRG1 fusion NSCLC or pancreatic cancer. Fusions in NRG1 (neuregulin) are rare but important, can be missed by DNA NGS, best detected with RNA-seq.

https://t.co/B6LdfVLXvg